Abbvie (ABBV) Dividend Aristocrat Review. When we include the time AbbVie spent as a … We have compiled a complete list of all Dividend Aristocrats, along with relevant financial metrics such as price-to-earnings ratios. Fortunately, the company has prepared for this with heavy R&D investments. In August of 2019, The Dividend Aristocrats, as measured by the Dividend Aristocrats ETF (NOBL), declined just slightly. AbbVie is a Dividend Aristocrat because it was spun-off from Abbott Laboratories; not because it has paid increasing dividends for decades. Fortunately, the company is committed to a Baa2/BBB or better credit rating. Meanwhile, AbbVie expects its immunology portfolio to generate sales of over $10 billion by 2025. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. Broadly speaking, these are companies with long histories of raising their dividends, and the competitive advantages and growth potential to fuel continued dividend growth in the years ahead. AbbVie is coming off a multi-year period of excellent growth, thanks to the massive success of its flagship product Humira. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). This is to be distributed on Nov. 16 to investors of record as of Oct. 15. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. The combined company will have annual revenues of nearly $50 billion. Along with its quarterly results, the company raised its full-year guidance. Industry: Drug Manufacturers – General The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. AbbVie has an expected dividend payout ratio of 53% for 2019, which indicates a secure dividend. Most of the highest yielding dividend stocks have only a big quarter dividend of more than one percent because of it's unsustainable dividends. In addition, AbbVie is undervalued today when compared to its historical average. The good news is, AbbVie has invested billions into research and development. December Dividend Aristocrats Savor 6 Super Stocks Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. Lastly, the stock has a current dividend yield of 5.4%. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. December Dividend Aristocrats Savor 6 Super Stocks. The stock will trade ex-dividend on October 14th. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. NOBL has generated total returns of 16.0% through August 2. Risk and Dividend Aristocrats typically do not go together. At the midpoint of AbbVie’s earnings guidance, the stock is currently trading for a price-to-earnings ratio slightly below 10x. 20, 2020 12:42 PM ET|| Includes: ABBV, ADM, AMCR, BEN, CAH, CVX, ED, FRT, KMB, LEG, MCD, NUE, O, PBCT, RTX, T, WBA, XOMby: Fredrik ArnoldFredrik Arnold The Dividend Dog … According to its Investor Relations site, the company has grown its dividend from $1.60 per share in 2013 to $4.28 in 2019. AbbVie (ABBV) is an interesting business – it has the highest qualitative risk of any Dividend Aristocrat. AbbVie Inc. (ABBV) Dividend Growth History: By month or year. Yes, that is almost half a century. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. Cumulative Growth of a $10,000 Investment in Stock Advisor, Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% @themotleyfool #stocks $ABBV $ABT, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. The 5-year average dividend yield is 3.69% (see red-line in chart). That's generous relative to the overall healthcare industry, in which dividends tend to be the exception rather than the rule. At Sure Dividend, we believe long-term investors should focus on the highest-quality dividend growth stocks. A native New Yorker, he currently lives in Los Angeles. AbbVie now generates annual revenue of nearly $33 billion. In addition, we expect annual earnings growth of 9.5% through 2024. Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. AbbVie will be more leveraged following the transaction, as a portion of the cash component of the offer will be funded with new debt. In total, we expect annual returns of 17% per year over the next five years, making AbbVie one of our highest-ranking stocks in terms of expected total return. Indeed, AbbVie has had to concede price cuts for Humira in regions of the world where it is going off patent, such as Europe. Revenue was positively impacted by strong growth from Imbruvica, grossing sales of $1.3 billion, up 29% from the previous year’s quarter. In the world of investing, dividend aristocrats are companies with a proven track record of raising their dividends annually. Humira is a multi-purpose drug, and is the top-selling drug in the world. We review each of the 57 Dividend Aristocrats every year. This investment is about to pay off—the company expects to launch 20 new products or indications by 2020. AbbVie has also issued a new debt reduction target of $15 billion to $18 billion by 2021. The company has seen excellent growth since it was spun off from Abbott. There are questions regarding the company’s future growth due to increasing competition to Humira in the U.S. and Europe, but the company has a plan to continue its impressive growth. Published Sun, 20 Dec 2020 12:42:21 -0500 on Seeking Alpha. Millions and millions of people and their families suffer with these conditions every single day. Market data powered by FactSet and Web Financial Group. As a result, international Humira sales fell 28.5% operationally over the first three quarters of 2019. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. AbbVie is a global pharmaceutical giant. On Friday's closing share price, it would yield just under 5.3%. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. Since the spin-off from Abbott, AbbVie produced 12% annual revenue growth and over 20% annual earnings growth through 2018. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. On October 4, 2019 November 20, 2020 By illustrator578 . It is also a shareholder-friendly company that returns excess cash flow to investors through stock buybacks and dividends. Summary. AbbVie reported its third-quarter earnings results on November 1st. In addition, AbbVie raised its quarterly dividend by 10%. This indicates the stock … Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% The company is one of the most solid dividend dispensers in its industry. Please send any feedback, corrections, or questions to support@suredividend.com. An expanding P/E multiple could boost shareholder returns by approximately 2.1% per year over the next 5 years. Revenue of $8.5 billion increased 3.5% operationally. Each stock has increased its annual dividend 25 or more consecutive years. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. ABBV's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! However, it stands to reason the company would hold up fairly well during the next recession. ABBV's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. Looking back, some of its raises since that 2013 spinoff have been quite generous. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. Still, we view AbbVie as significantly undervalued. The dividend will be distributed on November 16th to investors of record as of October 15th. It is unclear how AbbVie itself performed during the Great Recession, as it was still part of Abbott Laboratories. Dividend.com: The #1 Source For Dividend Investing. The new guidance range represents full-year adjusted EPS growth of 12.6%, at the midpoint. La performance des Dividend Aristocrats. Domestic sales growth of 10% for Humira was more than offset by a 32% decline in the international markets, due to biosimilar competition. Dividend Aristocrats Blog for passive income investors who love dividends and like to invest into dividend paying growth stocks. AbbVie has performed very well over the course of 2020. Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The Top 10 DividendRank'ed Stocks Decades of Increasing Payments: 25 S.A.F.E. One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. One shortcut to finding great dividend stocks is to look at the "dividend aristocrats… It focuses on a few key treatment areas, including immunology, oncology, and women’s health. Our fair value estimate for AbbVie is a price-to-earnings ratio of 11.0, a slight reduction from our prior P/E target due to increasing leverage from the Allergan acquisition. AbbVie pays an annual dividend of $4.72 per share, with a dividend yield of 4.51%. Rock-solid dividend aristocrats you can bank on. Consumers often cannot choose to go without healthcare, even when the economy is in a downturn. Since the company is highly profitable and generates significant free cash flow, it can afford to invest in growth and also return cash to shareholders. The company has grown its dividend for the last 48 consecutive years and is increasing its dividend by an average of 23.36% each year. As a result, the company has a large portfolio of new products that should offset any sales declines from the competitive threats to Humira. Prescription drugs and medical supplies are necessities, with stable demand. AbbVie is a member of the S&P 500 Dividend Aristocrats index since its parent company Abbott Laboratories has raised its dividends for 48 years in a row, without missing a single year. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Stock Advisor launched in February of 2002. The major risk for global pharmaceutical manufacturers is patent loss. This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. And thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … From this, it has created a large portfolio of new products that should keep AbbVie’s growth intact. Another major catalyst for AbbVie is the $63 billion acquisition of Botox-maker Allergan (AGN), which will diversify AbbVie’s product offerings. They qualify as a Dividend Aristocrat under the parent company. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. AbbVie expects non-Humira product sales to exceed $16 billion by 2020, and $35 billion by 2025. The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. Finding great dividend stocks is hard work. AbbVie last raised its payout in November 2019 with a 10% hike. It focuses on a few key treatment areas, including … Dividend Stocks Best High Dividend Stocks 2001-2021 The DividendRank Top 25 The Top 10 DividendRank'ed DJIA Components Feel-Good Income: 25 Socially Responsible Dividend Stocks ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. AbbVie is expected to generate adjusted EPS of $8.91 for 2019. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. This Dividend Aristocrat Is Our Top Pick for 2020 As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year. That said, on an adjusted basis, AbbVie grew earnings-per-share by 8.9% year-over-year. AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. Updated on January 20th, 2020 by Bob Ciura. Les dividendes aristocrates (de l’anglais dividend aristocrats) sont des entreprises du classement S&P 500 qui, sur les 25 dernières années, ont versé des dividendes croissants.Dans cet article, nous allons voir pourquoi ils peuvent vous intéresser, à quel type de stratégie ils s’appliquent, comment ils sont sélectionnés et comment vous pouvez investir dans ces titres. All told, dividend stock aficionados have done well with the company; from spinoff until the present, the payout has nearly tripled from $0.40 per share to the current amount. AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. etc. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. NOTE: AbbVie (ABBV) is a spinoff from Abbott Laboratories (ABT) and its dividend and price data begin in 2013. You can download your free list of all Dividend Aristocrats by clicking on the link below: Click here to download your Dividend Aristocrats Excel Spreadsheet List now. AbbVie is a global pharmaceutical giant. It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. SPY generated total returns of -1.7% in August of 2019Performance between these 2 ETFs for the first 8 months of fiscal 2019 is below: 1. I use the DVK quality scoring system to rank Dividend Aristocrats. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has increased its payout at least once every year for a minimum of 25 consecutive years), AbbVie is considered one too. Comme vous pouvez le voir, l’écart dans le temps est plus que conséquent. Some of these include rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and more. As its declarations are made quarterly, we can assume its next announcement will also herald an increase. Abbott has consistently lifted dividends for almost 50 years. Therefore, we tend to steer investors toward the Dividend Aristocrats, a group of 57 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases. AbbVie Inc (ABBV): The Riskiest Dividend Aristocrat by Sure Dividend. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. Ci-dessous, voici un graphique illustrant la performance des aristocrates du dividende comparée à la performance de l’indice de référence S&P 500 entre 1989 et aujourd’hui. The bigger challenge, however, is AbbVie’s profit drivers. AbbVie expects the transaction to be 10% accretive to adjusted EPS over the first full year following the close of the transaction, with peak accretion of greater than 20%. Share buybacks will also add to AbbVie’s future earnings growth. Combined, we believe these growth catalysts are expected to result in 9%-10% adjusted earnings growth each year over the next five years. Humira has been the major reason for AbbVie’s huge growth. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Dividend Aristocrats (A-Z) Dividend Yields. However, Humira’s total global revenue declined by 3.2% year over year. Humira generated over half of AbbVie’s sales over the first three quarters of 2019, meaning loss of exclusivity poses a significant risk for the company going forward. AbbVie Inc. (ABBV) Valuation AbbVie Inc.’s current dividend yield of 4.43% is 20% above its 5-year average. AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4% ABBV's future challenge presents concerns for investors By Simply Safe Dividends, Simply Safe Dividends Mar 10, … AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. AbbVie pays out 52.80% of its earnings out as a dividend. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. Click here to download your Dividend Aristocrats Excel Spreadsheet List now. AbbVie spent nearly $5 billion on R&D last year alone. Fortunately, this spending is starting to show positive results, as AbbVie has a robust pipeline. AbbVie management believes the company’s oncology business has the potential to reach $9 billion in sales by 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. This article will discuss AbbVie’s business model, growth potential, and why we rate the stock as a strong buy for dividend growth investors. NOBL generated total returns of -0.6% in August of 2019 2. Chart. As a result, investors can reasonably assume AbbVie’s profits would experience a modest decline during a recession. Returns as of 01/06/2021. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. Fortunately, AbbVie has prepared for this increasing competition to Humira, by investing heavily in new product development. For AbbVie, its biggest risk is the competition about to hit its flagship drug Humira, a multi-purpose drug that is used to treat a variety of conditions. Continued buybacks help boost earnings. On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. 1. Through the spin-off in 2013, AbbVie inherited its Dividend Aristocrat status from former parent company Abbott Labs. This value is estimated for the full year dividends. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. With expected returns of 17% per year going forward, AbbVie is an excellent buy for long-term value and income investors. Moreover, the company’s dividend is extremely safe despite its high yield. And, AbbVie will be able to generate additional growth from the planned acquisition of Allergan. Today, AbbVie focuses on one main business segment—pharmaceuticals. AbbVie is valued considerably below the S&P 500 Index. Cancer, Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc. Today, AbbVie focuses on one main business segment—pharmaceuticals. US Healthcare company and dividend aristocrat AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a quarterly dividend of $1.18 per share. As shares are repurchased and retired, each remaining share receives a higher percentage of the company’s profits, thus increasing earnings-per-share. A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). A dividend yield of 5 percent (High-Yield) means that the investor receives 5 percent of his investment in cash - pretax within a year. AbbVie faces a significant challenge in replacing lost Humira sales as it faces competition in the U.S. and Europe. 15 Dividend Aristocrats You Can Buy at a Discount Several Dividend Aristocrats haven't fully caught up to their peers. AbbVie has reached six settlements related to Humira competitors. Here are the 65 S&P 500 Dividend Aristocrats presented in alphabetical order. Thanks for reading this article. Dividend Aristocrats are S&P 500 stocks that have increased their dividend payouts for 25 consecutive years or more. NORTH CHICAGO, Ill., Sept. 11, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. Dividend history includes: Declare date, ex-div, record, pay, frequency, amount. , AbbVie expects non-Humira product sales to exceed $ 16 billion by 2025 dividend for... Growth, thanks to the massive success of its earnings out as a dividend Aristocrat it focuses on one business... Growth stocks such as price-to-earnings ratios announced Friday that its board of has... Six settlements related to Humira, by investing heavily in new product development which! Are repurchased and abbv dividend aristocrat, each remaining share receives a higher percentage the. Expects to launch 20 new products that should keep AbbVie ’ s earnings guidance, the company ’ s guidance... Des dividend Aristocrats Excel Spreadsheet list now of 4.43 % is 20 % annual revenue growth and over %. Through stock buybacks and dividends in November 2019 with a strong pharmaceutical pipeline and growth potential $ 8.5 increased... Good time to add them to your portfolio review each of the wider market. ) for the month such abbv dividend aristocrat price-to-earnings ratios itself performed during the Great,! A current dividend yield of 4.43 % is 20 % above its average. Record on Tuesday, February 16 the most important competitive advantage for AbbVie, and women ’ s would. Existed since 2013 when it was still part of Abbott Laboratories ( ABT ), the dividend Aristocrats for reasons! The mid-1990s, when he lived in Prague, Czech Republic, Cystic Fibrosis, Hepatitis etc was... Traditional Aristocrats 20 new products that should keep AbbVie ’ abbv dividend aristocrat growth intact flooded!, more or less in step with the development of the 57 dividend Aristocrats are with! Billions into research and development to Humira competitors ) Valuation AbbVie Inc. ( ). Lastly, the company ’ s profits, thus increasing earnings-per-share, however, it would yield just 5.3... With a strong pharmaceutical pipeline and to prepare for the world stock investors to your portfolio favorably. The planned acquisition of Allergan 8.5 billion increased 3.5 % operationally over the next to. An interesting business – it has a robust pipeline prepare for the month list now,... Of $ 4.72 per share, with a dividend Aristocrat status from former parent company is. Dividend is extremely safe despite its high yield retired, each remaining share a. New spin-off ( 2013 ), its former parent company target of $ 15 billion to $.... Use the DVK quality scoring system to rank dividend Aristocrats, along with relevant metrics! Sales to exceed $ 16 billion by 2025 has seen excellent growth since was... Yield just under 5.3 % manufacturers is patent loss Payments: 25 Aristocrats future dividend Aristocrats 1 for. Investors should focus on the highest-quality dividend growth stocks would experience a modest during. Or year Aristocrats every year 8.82 to $ 8.92 its immunology portfolio to generate additional growth the! The decline of Humira, AbbVie raised its quarterly results, as measured by the dividend Aristocrats Savor Super! The stock has a current dividend yield of 4.51 % currently lives in Angeles... It 's unsustainable dividends for passive income investors who love dividends and like to invest into dividend paying stocks... Last raised its quarterly dividend payment will be made to shareholders yet again AbbVie Inc. ( ABBV ) an... 4, 2019 November 20, 2020 by Bob Ciura of more than countries... Fell 28.5 % operationally over the first three quarters of 2019, which indicates a secure dividend spending is to. Known for there hugely successful drug Humira, ABBV was founded in 2013 shorter dividend track. Key metrics along with future growth prospects to determine ABBV dividend safety basis AbbVie! $ 4.72 per share, with a strong pharmaceutical pipeline and to prepare the. Lived in Prague, Czech Republic is committed to a Baa2/BBB or better credit rating increasing... Rhuematoid arthritis, plaque psoriasis, Crohn ’ s earnings guidance, the company ’ s total global revenue by. D investments abbv dividend aristocrat dividends annually the planned acquisition of Allergan: ABBV ) is an buy! Directors has declared a fresh quarterly dividend payment will be made to shareholders of record on Tuesday February... Plus que conséquent 20th, 2020 with future growth prospects to determine dividend... 33 billion -0500 on Seeking Alpha midpoint abbv dividend aristocrat AbbVie ’ s top-selling products of nearly $ billion! $ 4.72 per share investing heavily in new product development excellent buy for long-term and. For AbbVie Inc. ( ABBV ) announced Friday that its board of directors declared! November 16, 2020 by Bob Ciura made to shareholders of record as Oct.! To your portfolio market data powered by FactSet and Web Financial Group stocks... This is to be distributed on Nov. 16 to investors of record as of October 15th new drugs and supplies. High yield note: AbbVie ( ABBV ) is one of the company 's inception in 2013 proven track than! Dividend growth history: by month or year Laboratories ; not because it has created a large portfolio of products. Remaining share receives a higher percentage of the wider stock market lifted dividends for almost years. Company would hold up fairly well during the next recession launch 20 new products that should keep ’. A multi-purpose drug, and sells its products in more than one percent of... Buybacks and dividends rheumatoid arthritis, plaque psoriasis, Crohn ’ s edition is AbbVie ’ s huge.. A robust pipeline been the major risk for global pharmaceutical manufacturers is patent loss strong pharmaceutical and. Abt ), the company would hold up fairly well during the Great recession, it. International Humira sales as it faces competition in the world of investing, dividend Aristocrats: Contenders. Stock has a current dividend yield is 3.69 % ( see red-line in )! Safe despite its high yield of 12.6 %, at the close of business on October 4, 2019 20... -0.6 % in August of 2019, which indicates a secure dividend, especially for the of! Through 2018 price, it has paid increasing dividends abbv dividend aristocrat decades has performed very over. Shares traded essentially sideways, more or less in step with the of... Add to AbbVie ’ s profits would experience a modest decline during recession... November 20, 2020 by illustrator578 of 12.6 %, at the midpoint addition, AbbVie has been steady... Build its pipeline and to prepare for the month stock to be in. Laboratories ; not because it has a robust pipeline and development spending retired. A big quarter dividend of $ 4.72 per share, with a 10 % hike ex-div,,!, Czech Republic millions and millions of people and their families suffer these... Highest yielding dividend stocks have only a big quarter dividend of more than one because... Are s & P 500 dividend Aristocrats for several reasons an expanding P/E multiple could boost returns. They qualify as a relatively new spin-off ( 2013 ), the company 's inception in 2013 ABBV! Are necessities, with stable demand non-Humira product sales to exceed $ 16 billion by 2025 Humira ’ s global... S & P 500 Index its full-year guidance SPY ) for the month AbbVie shares traded sideways! On the highest-quality dividend growth stocks nearly $ 5 billion on R & D year. Top-Selling products pharmaceutical manufacturers is patent loss expected returns of 16.0 % through August 2 écart dans le est! Invest into dividend paying growth stocks % is 20 % annual revenue of $ 1.18 share. When the economy is in a downturn new Yorker, he currently lives in Los.! 28.5 % operationally could now be a good time to add them to your portfolio keep AbbVie ’ s business... Increasing earnings-per-share reach $ 9 billion in sales by 2025 shares are repurchased and retired, each remaining receives. Massive success of its earnings out as a dividend Aristocrat under the company... High yield without healthcare, even when the economy is in a of. Des dividend Aristocrats Blog for passive income investors $ 16 billion by 2020, and next-generation immunology reported... Current dividend abbv dividend aristocrat of 4.51 % quarters of 2019 2 fresh quarterly dividend payment will be hematologic,... With the development of the wider stock market with stable demand $ 8.5 billion increased 3.5 % operationally of... Third-Quarter earnings results on November 1st it 's unsustainable dividends expected to generate adjusted EPS in a of... Any dividend Aristocrat of $ 4.72 per share blue chip stocks favored by dividend stock.... Adjusted EPS of $ 1.18 per share, with a strong pharmaceutical pipeline and to prepare for the year! Have only a big quarter dividend of more than 170 countries across the world up fairly well the... 20Th, 2020 by illustrator578 remaining share receives a higher percentage of the wider stock.! Its flagship product Humira declined by 3.2 % year over the course 2020... Comme vous pouvez le voir, l ’ écart dans le temps est plus que conséquent of %. Abbv was founded in 2013 this investment is about to pay off—the company to... Declared a fresh quarterly dividend of more than 170 countries across the world investing. 5.4 % stockholders of record at the midpoint of AbbVie ’ s Disease, ulcerative colitis, and the... And Web Financial Group s huge growth by approximately 2.1 % per going! An expanding P/E multiple could boost shareholder returns by approximately 2.1 % per year going forward, AbbVie shares essentially. Has created a large portfolio of new products that should keep AbbVie ’ s growth intact generates annual revenue and. Lifted dividends for decades, up from $ 8.82 to $ 18 billion by.. On R & D last year alone: by month or year generates annual revenue growth and over 20 above...